HMPL-A580

N/A

Report date: 2026/04/10 20:01:49
First In Class

Base Information

Drug NameHMPL-A580
Drug Alias NameHMPL-A580HMPLA580
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionPhosphatidylinositol 3-kinase modulatorsAnti-Epidermal growth factor receptor erbB1
TargetsPhosphatidylinositol 3-kinaseEpidermal growth factor receptor erbB1
Therapy Area/IndicationsSolid tumoursNeoplasm Metastasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesHutchison Medipharma Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHutchmed (Hong Kong) LtdHutchison Medipharma Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeoplasm Metastasis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A